Research programme: malaria vaccine - Institut Pasteur/sanofi pasteur

Drug Profile

Research programme: malaria vaccine - Institut Pasteur/sanofi pasteur

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria in France (Parenteral)
  • 22 Oct 2008 Sanofi-aventis and Medicines for Malaria Venture enter into a collaboration to accelerate research and development of new antimalarial drugs
  • 15 Oct 2007 sanofi pasteur establishes a collaborative partnership with Institut Pasteur for the development of a malaria vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top